人类基因组计划与临床肿瘤学(13)
68、Thiesing,J.T., Ohno-Jones, S., Kolibaba, K. S., et al. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abi-positive cell. Blood, 2000,96:3195-3199.
69、Vigneri, P., and Wang, J. Y., Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABLtyrosine kinase. Nat.Med., 2001,7:228-234.
70、Yuena,Halsey J, Fisher G, et al. Phase Ⅰ/Ⅱtrial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc Am Soc Clin Oncol, 2001, 20: 1234a.
, 百拇医药
71、Perez-Soler R, Chachoua A, Huberman M, et al. A phase Ⅱtrial of the epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor OSI-774,following platinum-based chemotherapy, in patients with advanced, EGFR-expressing, non-small cell lung cancer. Proc Am Soc Clin Oncol, 2001, 20: 1235a.
72、沈靖，人类基因组计划与肿瘤预防研究面临的机遇，肿瘤，2000，20(1)：68-69。
73、Ismail, R. S., Baldwin, R. L., Fang, J., et al. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res., 2000, 60:6744-6749.
, 百拇医药
74、Szabo Cl, King MC. Inherited breast and ovarian cancer. Hum Mol Genet. 1995,4:1811-1817.
75、Lynch HT, Fusaro RM, Lvnch JF. Cancer genetics in the new era of molecular biology. In: Bradlow HL, Fishman J, Osborne MP,eds. Cancer Genetics ans the Environment. New York: New York Academy of Sciences; 1997,1-25.
76、Solomon JS, Brunicardi CF, Friedman JD. Evaluation and treatment of BRCA positive patients. Plast Reconst Surg. 2000, 105:714-719.
, 百拇医药
77、Friedman LC, Webb JA, Richards CS, et al. Psychological impact of receiving negative BRCA1 mutation test results in Ashkenazim. Genet Med. 1999,1:74-79.
78、Donis-Keller H, Dou S, Chi D, et al. Specific mutation in the PET proto-oncogene associated with MEN2a and FMTC. Hum Mol Genet. 1993, 2:851-859.
79、Wells SA, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactric thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Anm Surg, 1994, 220:237-250.
, 百拇医药
80、Elizabeth Pennisi, So many choices, so little money, Science, 2001, Oct5; 294(5540):82-85.
81、Lan Coulter, Genomic medicine: the sorcerer's new broom? The limitations of the human genome project. West J Med, 2001 Dec, 175(6): 424-426.
82、Edrrorial, Overoptimism about cancer, The Lancet, 2000, 355(9199): 157.
83、L. Barr and D.G.Evans. There may never be a final cure for breast cancer. EJSO, 2001, 27:338-339., 百拇医药(林嘉颖)
69、Vigneri, P., and Wang, J. Y., Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABLtyrosine kinase. Nat.Med., 2001,7:228-234.
70、Yuena,Halsey J, Fisher G, et al. Phase Ⅰ/Ⅱtrial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc Am Soc Clin Oncol, 2001, 20: 1234a.
, 百拇医药
71、Perez-Soler R, Chachoua A, Huberman M, et al. A phase Ⅱtrial of the epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor OSI-774,following platinum-based chemotherapy, in patients with advanced, EGFR-expressing, non-small cell lung cancer. Proc Am Soc Clin Oncol, 2001, 20: 1235a.
72、沈靖，人类基因组计划与肿瘤预防研究面临的机遇，肿瘤，2000，20(1)：68-69。
73、Ismail, R. S., Baldwin, R. L., Fang, J., et al. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res., 2000, 60:6744-6749.
, 百拇医药
74、Szabo Cl, King MC. Inherited breast and ovarian cancer. Hum Mol Genet. 1995,4:1811-1817.
75、Lynch HT, Fusaro RM, Lvnch JF. Cancer genetics in the new era of molecular biology. In: Bradlow HL, Fishman J, Osborne MP,eds. Cancer Genetics ans the Environment. New York: New York Academy of Sciences; 1997,1-25.
76、Solomon JS, Brunicardi CF, Friedman JD. Evaluation and treatment of BRCA positive patients. Plast Reconst Surg. 2000, 105:714-719.
, 百拇医药
77、Friedman LC, Webb JA, Richards CS, et al. Psychological impact of receiving negative BRCA1 mutation test results in Ashkenazim. Genet Med. 1999,1:74-79.
78、Donis-Keller H, Dou S, Chi D, et al. Specific mutation in the PET proto-oncogene associated with MEN2a and FMTC. Hum Mol Genet. 1993, 2:851-859.
79、Wells SA, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactric thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Anm Surg, 1994, 220:237-250.
, 百拇医药
80、Elizabeth Pennisi, So many choices, so little money, Science, 2001, Oct5; 294(5540):82-85.
81、Lan Coulter, Genomic medicine: the sorcerer's new broom? The limitations of the human genome project. West J Med, 2001 Dec, 175(6): 424-426.
82、Edrrorial, Overoptimism about cancer, The Lancet, 2000, 355(9199): 157.
83、L. Barr and D.G.Evans. There may never be a final cure for breast cancer. EJSO, 2001, 27:338-339., 百拇医药(林嘉颖)